Clinical trial · no report yet · Phase 3
KEYNOTE-630
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
- NCT03833167 ↗
- Terminated
- Merck Sharp & Dohme LLC
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 9 | |
| Podcasts | 8 | |
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Carcinoma, Squamous Cell
- Interventions
- Pembrolizumab; Placebo
- Arms
- Pembrolizumab · Experimental
- Placebo · Placebo comparator
- Enrollment
- 450
- Primary outcomes
- Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Apr 1, 2019
- Primary completion
- Jun 28, 2024
- Results posted
- Yes
- Registry record
- NCT03833167 · updated Sep 28, 2026